GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update

Rhea-AI Summary

GeoVax Labs, Inc. (Nasdaq: GOVX) will report its first quarter 2022 financial results on April 27, 2022, after market close. A conference call will be hosted at 4:30 p.m. ET on the same day to discuss the results and corporate updates. Participants must pre-register for the call to receive dial-in instructions. GeoVax is focused on developing vaccines and immunotherapies for infectious diseases and cancer, with clinical trials including COVID-19 vaccines and cancer treatments. The company holds over 70 patent applications across various research areas.

Positive

• Ongoing Phase 2 trials for GEO-CM04S1 against COVID-19.
• Gedeptin® has orphan drug status from the FDA for head and neck cancer treatment.
• Diverse product pipeline targeting multiple infectious diseases and cancers.

Negative

• None.

Conference call to be held Wednesday, April 27, at 4:30 p.m. Eastern Time

ATLANTA, GA, April 19, 2022 (GLOBE NEWSWIRE) --  via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, announces today that it will report first quarter 2022 financial results on Wednesday, April 27, 2022 after the market closes.

Management will host a conference call at 4:30 p.m. ET on Wednesday, April 27, 2022 to review financial results and provide an update on corporate developments.  Following management’s formal remarks, there will be a question-and-answer session.

Participants are asked to pre-register for the call via the following link:

https://dpregister.com/sreg/10165192/f224e0bbb0

Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay.  Those without Internet access or who are unable to pre-register may dial in by calling 1-866-777-2509 (domestic) or 1-412-317-5413 (international).  All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the GeoVax call.

The conference call will be available through a live webcast found here:

https://services.choruscall.com/mediaframe/webcast.html?webcastid=aUvzOB1O

A webcast replay of the call will be available via the same link as the live webcast approximately one hour after the end of the call through July 27, 2022.  A telephonic replay of the call can be accessed by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 5386762.  The telephonic replay will be available until May 11, 2022.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer using novel proprietary platforms. GeoVax’s product pipeline includes two ongoing Phase 2 clinical trials of GEO-CM04S1 (formerly COH04S1) for COVID-19 as a universal booster vaccine to mRNA vaccines authorized by the U.S. Food and Drug Administration (FDA) and as a primary vaccine for use in immunocompromised patients. In addition to GEO-CM04S1 for COVID-19, GeoVax is developing GEO-CM02 as a pan-coronavirus vaccine. The Company is also conducting a Phase 1/2 clinical trial of Gedeptin® for treatment of head and neck cancer. Gedeptin® has been granted orphan drug status by the FDA. Additional research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property stands at over 70 granted or pending patent applications spread over 20 patent families.

For additional information about GeoVax, visit our website: www.geovax.com.

Contact:

GeoVax Labs, Inc.

678-384-7220

investor@geovax.com

FAQ

What are GeoVax Labs' financial results announcement dates for 2022?

GeoVax Labs will announce its first quarter 2022 financial results on April 27, 2022.

When is the conference call for GeoVax Labs' financial results?

The conference call is scheduled for April 27, 2022, at 4:30 p.m. ET.

What clinical trials is GeoVax Labs currently conducting?

GeoVax is conducting Phase 2 trials for GEO-CM04S1 and a Phase 1/2 trial for Gedeptin®.

What is the significance of GEO-CM04S1 in GeoVax's pipeline?

GEO-CM04S1 is a universal booster vaccine for COVID-19 and a primary vaccine for immunocompromised patients.

What status has Gedeptin® received from the FDA?

Gedeptin® has been granted orphan drug status by the FDA for the treatment of head and neck cancer.